Nu-Med Plus Inc. applies for Innovative Patent on Reactive Tube Coating
Nu-Med Plus Inc.
Jun. 05, 2018
SALT LAKE CITY, June 05, 2018 (GLOBE NEWSWIRE) -- Nu-Med Plus, Inc. (OTCQB:NUMD), a medical device company which explores and develops medical applications of new technologies in the medical field, announced its patent filing for its pioneering chemically reactive coating. The coating ensures that only a contaminant free nitric oxide, a life saving drug for neonates, reaches the patient.
Nu-Med Plus has developed a distinctive method for a reactive coating that chemically bonds or adheres to the inside surface of common medical gas delivery tubing. The coating essentially removes toxic contaminants that are found in nitric oxide delivery systems. The technique was developed to augment Nu-Med’s capability to deliver high purity Inhaled Nitric Oxide(INO) to the patient at point of use. A patent has been applied for protecting this novel advancement.
Inhaled Nitric oxide(INO) is a medically essential gas that is presently used in Neonate Hypoxia therapy (inadequate oxygen level in newborns), COPD and other pulmonary problems and may have future applications for a variety of global diseases and complications that are currently being investigated.
“The Nu-Med Plus goal is to increase its intellectual property portfolio by developing exceptional methods for the distribution of Inhaled Nitric Oxide(INO) and to safeguard its low cost INO technology which will enable us to add value to the company and increases our competitive advantage," commented Mr. Jeff Robins, President and CEO of Nu-Med Plus.
Nu-Med Plus, Inc. is a medical device development company created to explore medical applications of newly developed technologies. The strategy is to focus on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of inhaled nitric oxide gas for therapeutic use. For more information please visit www.nu-medplus.com.
Forward-Looking StatementsInformation set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.
Contact: Jeff Robins President 801-746-3570